Helius Medical Technologies, Inc. Announces Pricing of $6.4 Million Public Offering
06 mai 2024 22h15 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., May 06, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Announces Preliminary CMS Payment Determination of Reimbursement for Portable Neuromodulation Stimulator (PoNS®)
06 mai 2024 09h00 HE
|
Helius Medical Technologies, Inc.
-- The Centers for Medicare & Medicaid Services (CMS) released its preliminary Medicare payment determinations for the PoNS Controller and Mouthpiece -- -- Public Meeting Scheduled for May 29,...
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center
24 avr. 2024 09h05 HE
|
Helius Medical Technologies, Inc.
-- Helius Medical and Shepherd Center partner on a study that aims at rehabilitating walking mobility in people recovering from stroke ---- Shepherd Center, a top neurorehabilitation hospital, is the...
Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™
03 avr. 2024 07h05 HE
|
Helius Medical Technologies, Inc.
-- Lovell is an approved supplier to the U.S. Department of Veterans Affairs (VA) and Department of Defense (DoD) ---- Over 28,000 cases of multiple sclerosis (MS) are reported to the VA annually -- ...
Helius Medical Technologies, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 16h05 HE
|
Helius Medical Technologies, Inc.
-- Company to host call at 4:30pm today -- NEWTOWN, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused...
Helius Medical Technologies, Inc. to Release Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
15 mars 2024 07h05 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke
12 mars 2024 08h59 HE
|
Helius Medical Technologies, Inc.
-- Enrollment of at least ten patients at Brooks Rehabilitation will begin this month ---- Study will evaluate the use of Portable Neuromodulation Stimulator (PoNS®) for gait and balance deficits in...
Helius Medical Technologies, Inc. to Present at the 36th Annual ROTH Conference
07 mars 2024 07h00 HE
|
Helius Medical Technologies, Inc.
NEWTOWN, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic...
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller
04 mars 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Significant step toward reimbursement for the only medical device approved in the U.S. for treatment of gait deficit due to multiple sclerosis (“MS”) -- -- Proceeds from recent stock issuances...
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients
06 févr. 2024 07h00 HE
|
Helius Medical Technologies, Inc.
-- Studies uses Portable Neuromodulation Stimulator (PoNS®) to evaluate cranial-nerve non-invasive neuromodulation for gait/balance deficits in stroke patients -- -- Interaction with FDA on...